Injectable treatment may help support the bodys natural antioxidant defenses when clinically appropriate
In patients with DM2 the incretin response is diminished, but the insulinotropic effect of GLP-1 is conserved.28 Under normal conditions GLP-1 has a short half-life (approximately 2 min), as it is rapidly degraded by dipeptidylpeptidase 4, so GLP-1 analogues resistant to this enzyme have been developed for the treatment of DM2.29 arGLP-1: glucagon-like peptide 1 receptor agonist
It has significantly higher bioavailability, is better retained by the body, and is the form used in most clinical research
& Little, F
While GLP-1 RAs are well-established in the treatment of T2D, their metabolic effects in PD may benefit from a more detailed and context-specific assessment, particularly regarding body mass index (BMI), fat mass, and appetite
Now, with advancements in medical weight management, our providers also offer semaglutide weight loss programs for qualifying patients